Dolznig Helmut

Prof. Dr. Dolznig Helmut


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Mutation Research - Reviews in Mutation Research
Verified
Journal Article
Closed access
NKNina Kramer
Nina Kramer
AWAngelika Walzl
Angelika Walzl
CUChristine Unger
Christine Unger
MRMargit Rosner
Margit Rosner
GKGeorg Krupitza
Georg Krupitza
DHDolznig Helmut
Dolznig Helmut

1 January 2016 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
AEAndrew Ewald
Andrew Ewald
ARAngelika Riedl
Angelika Riedl
MSMichaela Schlederer
Michaela Schlederer
KPKaroline Pudelko
Karoline Pudelko
MSMira Stadler
Mira Stadler
DHDolznig Helmut
Dolznig Helmut
3D cancer models are used as preclinical systems to mimic physiologic drug response. We provide evidence for robust changes of proliferation and metabolic capacity in 3D by systematically analyzing spheroids of colon cancer cell lines. Spheroids showed relative lower AKT/mTOR/S6K activities compared to cells cultured in 2D. We identified spatial alterations in signaling, as the level of phospho-rpS6 decreased from the spheroid surface to the center, closely recapitulating the tumor areas around vessels in vivo. These 3D-models displayed augmented anti-tumor response to AKT/mTOR/S6K- or MAPK-pathway inhibition compared to 2D. Inhibition of AKT/mTOR/S6K resulted in elevated ERK phosphorylation in 2D, whereas under these conditions MAPK-signaling was reduced in spheroids. Inhibition of the MAPK-pathway led to decreased AKT/mTOR/S6K-signaling in 3D but not in 2D. These data indicate a distinct rewiring of signaling in 3D and during treatment. Detached tumor cell clusters in vessels, in addition to circulating single tumor cells, play a putative role in metastasis in human cancers. Hence, the understanding of signaling in spheroids and the response in the 3D models upon drug treatment might be beneficial for anti-cancer therapies.

30 October 2019 in Angiogenesis
Verified
Journal Article
Open access
PDF file
DUDaniela Unterleuthner
Daniela Unterleuthner
PNPatrick Neuhold
Patrick Neuhold
KSKatharina Schwarz
Katharina Schwarz
LJLukas Janker
Lukas Janker
BNBenjamin Neuditschko
Benjamin Neuditschko
DHDolznig Helmut
Dolznig Helmut
WNT2 acts as a pro-angiogenic factor in placental vascularization and increases angiogenesis in liver sinusoidal endothelial cells (ECs) and other ECs. Increased WNT2 expression is detectable in many carcinomas and participates in tumor progression. In human colorectal cancer (CRC), WNT2 is selectively elevated in cancer-associated fibroblasts (CAFs), leading to increased invasion and metastasis. However, if there is a role for WNT2 in colon cancer, angiogenesis was not addressed so far. We demonstrate that WNT2 enhances EC migration/invasion, while it induces canonical WNT signaling in a small subset of cells. Knockdown of WNT2 in CAFs significantly reduced angiogenesis in a physiologically relevant assay, which allows precise assessment of key angiogenic properties. In line with these results, expression of WNT2 in otherwise WNT2-devoid skin fibroblasts led to increased angiogenesis. In CRC xenografts, WNT2 overexpression resulted in enhanced vessel density and tumor volume. Moreover, WNT2 expression correlates with vessel markers in human CRC. Secretome profiling of CAFs by mass spectrometry and cytokine arrays revealed that proteins associated with pro-angiogenic functions are elevated by WNT2. These included extracellular matrix molecules, ANG-2, IL-6, G-CSF, and PGF. The latter three increased angiogenesis. Thus, stromal-derived WNT2 elevates angiogenesis in CRC by shifting the balance towards pro-angiogenic signals.

2 May 2011 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DKDontscho Kerjaschki
Dontscho Kerjaschki
ZBZsuzsanna Bago-Horvath
Zsuzsanna Bago-Horvath
MRMargaretha Rudas
Margaretha Rudas
VSVeronika. Sexl
Veronika. Sexl
CSChristine Schneckenleithner
Christine Schneckenleithner
GKGeorg Krupitza
Georg Krupitza
In individuals with mammary carcinoma, the most relevant prognostic predictor of distant organ metastasis and clinical outcome is the status of axillary lymph node metastasis. Metastases form initially in axillary sentinel lymph nodes and progress via connecting lymphatic vessels into postsentinel lymph nodes. However, the mechanisms of consecutive lymph node colonization are unknown. Through the analysis of human mammary carcinomas and their matching axillary lymph nodes, we show here that intrametastatic lymphatic vessels and bulk tumor cell invasion into these vessels highly correlate with formation of postsentinel metastasis. In an in vitro model of tumor bulk invasion, human mammary carcinoma cells caused circular defects in lymphatic endothelial monolayers. These circular defects were highly reminiscent of defects of the lymphovascular walls at sites of tumor invasion in vivo and were primarily generated by the tumor-derived arachidonic acid metabolite 12S-HETE following 15-lipoxygenase-1 (ALOX15) catalysis. Accordingly, pharmacological inhibition and shRNA knockdown of ALOX15 each repressed formation of circular defects in vitro. Importantly, ALOX15 knockdown antagonized formation of lymph node metastasis in xenografted tumors. Furthermore, expression of lipoxygenase in human sentinel lymph node metastases correlated inversely with metastasis-free survival. These results provide evidence that lipoxygenase serves as a mediator of tumor cell invasion into lymphatic vessels and formation of lymph node metastasis in ductal mammary carcinomas.

1 July 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
DHDolznig Helmut
Dolznig Helmut
CRChristian Rupp
Christian Rupp
CPChristina Puri
Christina Puri
CHChristian Haslinger
Christian Haslinger
NSNorbert Schweifer
Norbert Schweifer
PGPilar Garin-Chesa
Pilar Garin-Chesa

17 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
EKE. Koncina
E. Koncina
MNM. Nurmik
M. Nurmik
VPV. I. Pozdeev
V. I. Pozdeev
CGC. Gilson
C. Gilson
MTM. Tsenkova
M. Tsenkova
ELElisabeth Letellier
Elisabeth Letellier
Fibroblasts have a considerable functional and molecular heterogeneity and can play various roles in the tumor microenvironment. Here we identify a pro-tumorigenic IL1R1+, IL-1-high-signaling subtype of fibroblasts, using multiple colorectal cancer (CRC) patient single cell sequencing datasets. This subtype of fibroblasts is linked to T cell and macrophage suppression and leads to increased cancer cell growth in 3D co-culture assays. Furthermore, both a fibroblast-specific IL1R1 knockout and IL-1 receptor antagonist Anakinra administration reduce tumor growth in vivo. This is accompanied by reduced intratumoral Th17 cell infiltration. Accordingly, CRC patients who present with IL1R1-expressing cancer-associated-fibroblasts (CAFs), also display elevated levels of immune exhaustion markers, as well as an increased Th17 score and an overall worse survival. Altogether, this study underlines the therapeutic value of targeting IL1R1-expressing CAFs in the context of CRC.